Nicolas Mounier

Also affiliated with Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, La Ligue Contre le Cancer

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial”.

Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

The Lancet Haematology(2023)10.1016/s2352-3026(23)00157-6

N/A

0.847DataRank · unranked

32 citations

Page C. Moore, Milan Bimali, Jeanette Y. Lee, Michelle A. Rudek, Amy Chadburn +22 more

Faculty Opinions recommendation of Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature(2013)10.3410/f.718178615.793487196

N/A

0DataRank · unranked

0 citations

Nicolas Mounier